CANTON, Mass.--(BUSINESS WIRE)-- EquipNet Auctions has been selected by Myrexis, Inc. to conduct a global webcast auction as a result of the company’s decision to suspend development activity on all its preclinical and clinical programs in February 2012. All bidding will be conducted online beginning on November 1 at 10 AM local time. Bidders can pre-register for the auction and view the entire auction details including inspection times, terms, and a complete catalog of available equipment at www.EquipNet.com/Myrexis-PR.
Myrexis is a biopharmaceutical company that has generated a pipeline of differentiated drug candidates in oncology and autoimmune diseases. The project includes the entire contents of the closed plant, including: late-model mass spectrometers and HPLCs- Agilent 6510 Q-TOF; 6410 Triple Quad Agilent 6210 TOFs; Agilent LC/MSD TOFs; Waters Micromass LCT Premier; BD Pathways Imaging System, Varian 400 Mhz NMR; Agilent 1200 and 1100 HPLCs; and Shimadzu Prominence UPLCs, Microscopes & More!
EquipNet’s Managing Director of BioTech, Dennis Higgins, is excited by the variety of items available at the facility. “The Myrexis facility houses hundreds of late-model, high end lab equipment. The quality of these HPLCs, Mass Spectrometers, UPLCs and Microplate readers are a real treat for our buyers. Savvy companies can purchase surplus assets from a leading drug development and discovery company, at a fraction of the cost of purchasing it new,” says Higgins.
EquipNet is a leading provider of proactive asset management solutions and services to leading corporations in the biotech, pharmaceutical, chemical, food, beverage, and personal care industries, such as Novartis, Johnson and Johnson, Sanofi Aventis, Merck and many others. EquipNet’s vision is to revolutionize the way companies manage their surplus assets by maximizing financial returns and minimizing the risks associated with idle capital assets. For more information, please visit: http://www.EquipNet.com.
Ben Potenza, 781-821-3482